Teva has changed the dynamics of the generic NuvaRing (etonogestrel/ethinyl estradiol) market in the US after receiving approval for and launching its generic version of Merck & Co’s 0.120mg/0.015mg per day vaginal ring contraceptive.
Teva Takes On Amneal With Second US NuvaRing Rival
Israeli Firm Gains Approval For And Launches Vaginal Ring Contraceptive
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
